Alzheimer?s disease (AD) is characterized by the accumulation of multiple proteins including (APP)/A?, Tau, TDP-43 and alpha-synuclein (?-syn). The mechanisms are not completely understood however alterations in protein aggregate clearance including endosomal sorting complex required for transport (ESCRT) mediated autophagy might be involved. For the previous period of funding, the focus was to investigate the role of autophagy in the mechanisms of propagation and clearance of ? -syn and to develop new immunotherapies for the Dementia with Lewy bodies (DLB). We found that ? -syn interferes with intracellular trafficking and autophagy and that treatment with antibodies reduced propagation and toxicity. We published over 150 manuscripts and 3 of our programs targeting ? -syn have advanced to Phase I clinical trials. For the renewal we will investigate the role of ? -syn as a mediator of the toxicity of A? to selected neuronal populations in AD. Our HYPOTHESIS is that via interactions with Rabs and ESCRTIII proteins, ? -syn aggregates interfere with neuronal endosomal transport of neurotrophic factors (NTFs) leading to selective neuronal damage. Our OBJECTIVES will be to: i) investigate the role of ? -syn as mediator of the selective neuronal loss in AD by interfering with Rabs and ESCRTIII leading to defective transport of NTFs and ii) assess if brain-penetrating nucleotides targeting ? -syn might reverse the endosomal alterations and protect selected networks from degenerating in AD. Our revised AIMS are to: 1) Investigate in neuronal cultures the mechanisms through which ? -syn mediates selective neuronal vulnerability in AD via alterations in Rabs and ESCRTIII; 2) To determine in vivo if conditional ablation of ? -syn in specific neuronal populations in APP mice ameliorates neurodegeneration and functional alterations and 3) To evaluate the neuroprotective effects of brain targeted ? -syn siRNA in APP tg models. These goals are in agreement with the NIA 2012 and 2015 AD Summit Research Recommendations. A better understanding of the mechanisms underlying selective vulnerability in AD is crucial for developing novel therapeutics targeting ? -syn.

Public Health Relevance

Alzheimer?s disease (AD) which affects 10 million Americans is characterized by the accumulation of multiple proteins including (APP)/A?, Tau, TDP-43 and ? -synuclein (? -syn). This proposal will investigate the role of ?- syn as mediator of the selective neuronal loss in AD and will develop novel therapeuties targeting ? -syn.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG018440-17
Application #
9534491
Study Section
Cellular and Molecular Biology of Neurodegeneration Study Section (CMND)
Program Officer
Opanashuk, Lisa A
Project Start
2001-09-01
Project End
2022-05-31
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
17
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Neurosciences
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Chen, Xu-Qiao; Fang, Fang; Florio, Jazmin B et al. (2018) T-complex protein 1-ring complex enhances retrograde axonal transport by modulating tau phosphorylation. Traffic 19:840-853
Spencer, Brian; Brüschweiler, Sven; Sealey-Cardona, Marco et al. (2018) Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathol 136:69-87
Ngolab, Jennifer; Trinh, Ivy; Rockenstein, Edward et al. (2017) Brain-derived exosomes from dementia with Lewy bodies propagate ?-synuclein pathology. Acta Neuropathol Commun 5:46
Huang, Timothy Y; Zhao, Yingjun; Jiang, Lu-Lin et al. (2017) SORLA attenuates EphA4 signaling and amyloid ?-induced neurodegeneration. J Exp Med 214:3669-3685
Valera, Elvira; Spencer, Brian; Mott, Jennifer et al. (2017) MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy. Front Mol Neurosci 10:329
Adamowicz, David H; Roy, Subhojit; Salmon, David P et al. (2017) Hippocampal ?-Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and Is Consistent with Spread of Pathology. J Neurosci 37:1675-1684
Valera, Elvira; Spencer, Brian; Fields, Jerel A et al. (2017) Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathol Commun 5:2
You, Jason C; Muralidharan, Kavitha; Park, Jin W et al. (2017) Epigenetic suppression of hippocampal calbindin-D28k by ?FosB drives seizure-related cognitive deficits. Nat Med 23:1377-1383
El-Agnaf, Omar; Overk, Cassia; Rockenstein, Edward et al. (2017) Differential effects of immunotherapy with antibodies targeting ?-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiol Dis 104:85-96
Ihse, Elisabet; Yamakado, Hodaka; van Wijk, Xander M et al. (2017) Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell type. Sci Rep 7:9008

Showing the most recent 10 out of 205 publications